Rab Diagnostics

Executive Summary

Rab Diagnostics is a Norwegian precision medicine company addressing a critical challenge in oncology: selecting the right patients for Antibody-Drug Conjugate (ADC) therapies. ADCs have revolutionized cancer treatment but their efficacy varies widely due to heterogeneous expression of target antigens and intracellular trafficking defects. Rab Diagnostics' proprietary RabCANCER platform analyzes Rab-GTPase proteins, which are essential for ADC internalization and trafficking within cancer cells. By identifying predictive biomarkers, the company aims to stratify patients who are most likely to benefit from specific ADCs, thereby improving response rates, reducing unnecessary toxicity, and lowering healthcare costs. The company has been active since 2003 and has reached an 'Approved' stage, indicating a mature technology platform ready for clinical translation. With the explosive growth of the ADC market—expected to exceed $30 billion by 2030—Rab Diagnostics is well-positioned to become a key enabler of precision oncology. Its diagnostic tools could be integrated into drug development pipelines to enrich clinical trials, accelerate regulatory approvals, and extend product life cycles. The company's focus on intracellular trafficking rather than just target expression offers a unique differentiator in a competitive biomarker landscape. Successful commercial partnerships with leading ADC developers or diagnostic companies could unlock significant value. Upcoming catalysts include the publication of clinical validation studies, potential strategic collaborations, and regulatory milestones for its diagnostic assays.

Upcoming Catalysts (preview)

• Q4 2026Publication of Clinical Validation Data for RabCANCER Biomarker Panel50% success
• H1 2027Strategic Partnership or Licensing Deal with Major ADC Developer40% success
• 2027Regulatory Approval (CE Mark or FDA) for First Diagnostic Test30% success